-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rebamipide in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebamipide in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebamipide in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Rebamipide (DWP-DN11)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ipilimumab in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ipilimumab in Soft Tissue Sarcoma Drug Details: Ipilimumab (Yervoy, Winglore)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SORC-13 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SORC-13 in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SORC-13 in Prostate Cancer Drug Details: SORC-13 is under development for...
-
Product Insights
Salivary Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Salivary Gland Cancer - Drugs In Development, 2023’, provides an overview of the Salivary Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenoid Cystic Carcinoma (ACC) - Drugs In Development, 2023’, provides an overview of the Adenoid Cystic Carcinoma (ACC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenoid Cystic Carcinoma (ACC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor Of The Gastrointestinal Tract - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor Of The Gastrointestinal Tract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Mesenchymal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Nasopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nasopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Nasopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...